{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:22:04Z","timestamp":1760833324055,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":2870,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.breast.2011.05.006","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T03:35:04Z","timestamp":1309923304000},"page":"510-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Renal safety of ibandronate 6\u00a0mg infused over 15\u00a0min versus 60\u00a0min in breast cancer patients with bone metastases: A randomized open-label equivalence trial"],"prefix":"10.1016","volume":"20","author":[{"given":"Xavier","family":"Pivot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fawzia","family":"Mefti-Lacheraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Lefeuvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Letessier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Morvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"D\u00fcr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Frimat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2011.05.006_bib1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2011.05.006_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdi162","article-title":"Bisphosphonates in breast cancer","volume":"16","author":"Coleman","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.05.006_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.05.006_bib4","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.breast.2011.05.006_bib5","first-page":"719","article-title":"Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review","volume":"17","author":"Diel","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.breast.2011.05.006_bib6","first-page":"1125","article-title":"Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review","volume":"26","author":"Miller","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.breast.2011.05.006_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.breast.2011.05.006_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/annonc\/mdh079","article-title":"Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients","volume":"15","author":"Marx","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.05.006_bib9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/annonc\/mdf236","article-title":"A\u00a0comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients","volume":"13","author":"Poole","year":"2002","journal-title":"Ann Oncol"},{"issue":"10 Suppl","key":"10.1016\/j.breast.2011.05.006_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","article-title":"Preclinical perspectives on bisphosphonate renal safety","volume":"1","author":"Body","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2011.05.006_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0300-483X(03)00257-9","article-title":"The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats","volume":"191","author":"Pfister","year":"2003","journal-title":"Toxicology"},{"key":"10.1016\/j.breast.2011.05.006_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1742-7843.2005.pto_160.x","article-title":"Acute renal effects of intravenous bisphosphonates in the rat","volume":"97","author":"Pfister","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.breast.2011.05.006_bib13","first-page":"299","article-title":"Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results","volume":"15","author":"Body","year":"2006","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.breast.2011.05.006_bib14","first-page":"653","article-title":"Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer","volume":"18","author":"Heras","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.breast.2011.05.006_bib15","first-page":"877","article-title":"Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy","volume":"12","author":"Pecherstorfer","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.breast.2011.05.006_bib16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdn038","article-title":"Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study","volume":"19","author":"von Moos","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.05.006_bib17","first-page":"463","article-title":"Bisphosphonate infusions: patient preference, safety and clinic use","volume":"12","author":"Chern","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.breast.2011.05.006_bib18","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","article-title":"Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study","volume":"22","author":"Mancini","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.05.006_bib19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.05.006_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/14796694.1.5.593","article-title":"Ibandronate: efficacy in the treatment of metastatic bone disease","volume":"1","author":"Diel","year":"2005","journal-title":"Future Oncol"},{"issue":"10 Suppl","key":"10.1016\/j.breast.2011.05.006_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1634\/theoncologist.10-90001-8","article-title":"Efficacy of ibandronate in metastatic bone disease: review of clinical data","volume":"1","author":"Bell","year":"2005","journal-title":"Oncologist"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977611001226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977611001226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:28:14Z","timestamp":1760776094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977611001226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0960977611001226"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2011.05.006","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal safety of ibandronate 6\u00a0mg infused over 15\u00a0min versus 60\u00a0min in breast cancer patients with bone metastases: A randomized open-label equivalence trial","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2011.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}